Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea - 05/06/24
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Abstract |
Background |
There is growing evidence that the coronavirus disease 2019 (COVID-19) vaccination can affect the regulation of the immune system, leading to the development of autoimmune diseases. However, the autoimmune adverse events (AEs) after COVID-19 vaccination remain largely unclear.
Objective |
We sought to investigate the autoimmune AEs after COVID-19 vaccination from a population-based cohort in South Korea.
Methods |
A total of 4,203,887 participants, representing 50% of the population residing in Seoul, were recruited from the National Health Insurance Service database and then divided into 2 groups on the basis of COVID-19 vaccination. The cumulative incidence, hazard ratios (HRs), and 95% CIs of autoimmune AEs were assessed following COVID-19 vaccination.
Results |
The incidence of vitiligo has been observed to be significantly higher in the vaccination group compared with the no vaccination group. The cumulative incidence of vitiligo began to show a significant difference starting 2 weeks after vaccination, and it reached 2.2% in the vaccination group and 0.6% in the no vaccination group by 3 months after COVID-19 vaccination. Vitiligo (HR, 2.714; 95% CI, 1.777-4.146) was an increased risk among autoimmune AEs. Furthermore, the risk of vitiligo was the highest for heterologous vaccination (HR, 3.890; 95% CI, 2.303-6.573) compared with using cDNA vaccine (HR, 2.861; 95% CI, 1.838-4.453) or mRNA vaccine (HR, 2.475; 95% CI, 1.607-3.813).
Conclusions |
Vitiligo as an autoimmune AE was noted to be substantially higher in the COVID-19–vaccinated group compared with the controls. Therefore, the occurrence of vitiligo could be considered as one of the significant AEs post–COVID-19 vaccination.
El texto completo de este artículo está disponible en PDF.Key words : COVID-19, vaccination, vitiligo, autoimmune adverse events, complications
Abbreviations used : AE, AIH, AS, CCI, COPD, COVID-19, DC, DM, GSEA, GTEx, HPA, HR, HT, HTN, IBD, IRB, NHIS, OR, PBC, RA, SARS-CoV-2
Esquema
Vol 153 - N° 6
P. 1711-1720 - juin 2024 Regresar al número
Artículo precedente
- Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data
- Nicholas L. Rider, Ahuva Truxton, Tracy Ohrt, Irene Margolin-Katz, Mary Horan, Harold Shin, Roger Davila, Vanessa Tenembaum, Jessica Quinn, Vicki Modell, Fred Modell, Jordan S. Orange, Almut Branner, Cynthia Senerchia
- Joint transcriptomic and cytometric study of children with peanut allergy reveals molecular and cellular cross talk in reaction thresholds
- Lingdi Zhang, Yoojin Chun, Zoe Arditi, Galina Grishina, Tracy Lo, Kayla Wisotzkey, Charuta Agashe, Alexander Grishin, Julie Wang, Hugh A. Sampson, Scott Sicherer, M. Cecilia Berin, Supinda Bunyavanich
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.